Cargando…
Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker
The purpose of this study is to identify prognostic markers and treatment targets using a clinically certified sequencing panel in multiple myeloma. We performed targeted sequencing of 578 individuals with plasma cell neoplasms using the FoundationOne Heme panel and identified clinically relevant ab...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386330/ https://www.ncbi.nlm.nih.gov/pubmed/28234347 http://dx.doi.org/10.1038/bcj.2017.12 |
_version_ | 1782520747886903296 |
---|---|
author | Chavan, S S He, J Tytarenko, R Deshpande, S Patel, P Bailey, M Stein, C K Stephens, O Weinhold, N Petty, N Steward, D Rasche, L Bauer, M Ashby, C Peterson, E Ali, S Ross, J Miller, V A Stephens, P Thanendrarajan, S Schinke, C Zangari, M van Rhee, F Barlogie, B Mughal, T I Davies, F E Morgan, G J Walker, B A |
author_facet | Chavan, S S He, J Tytarenko, R Deshpande, S Patel, P Bailey, M Stein, C K Stephens, O Weinhold, N Petty, N Steward, D Rasche, L Bauer, M Ashby, C Peterson, E Ali, S Ross, J Miller, V A Stephens, P Thanendrarajan, S Schinke, C Zangari, M van Rhee, F Barlogie, B Mughal, T I Davies, F E Morgan, G J Walker, B A |
author_sort | Chavan, S S |
collection | PubMed |
description | The purpose of this study is to identify prognostic markers and treatment targets using a clinically certified sequencing panel in multiple myeloma. We performed targeted sequencing of 578 individuals with plasma cell neoplasms using the FoundationOne Heme panel and identified clinically relevant abnormalities and novel prognostic markers. Mutational burden was associated with maf and proliferation gene expression groups, and a high-mutational burden was associated with a poor prognosis. We identified homozygous deletions that were present in multiple myeloma within key genes, including CDKN2C, RB1, TRAF3, BIRC3 and TP53, and that bi-allelic inactivation was significantly enriched at relapse. Alterations in CDKN2C, TP53, RB1 and the t(4;14) were associated with poor prognosis. Alterations in RB1 were predominantly homozygous deletions and were associated with relapse and a poor prognosis which was independent of other genetic markers, including t(4;14), after multivariate analysis. Bi-allelic inactivation of key tumor suppressor genes in myeloma was enriched at relapse, especially in RB1, CDKN2C and TP53 where they have prognostic significance. |
format | Online Article Text |
id | pubmed-5386330 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-53863302017-04-26 Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker Chavan, S S He, J Tytarenko, R Deshpande, S Patel, P Bailey, M Stein, C K Stephens, O Weinhold, N Petty, N Steward, D Rasche, L Bauer, M Ashby, C Peterson, E Ali, S Ross, J Miller, V A Stephens, P Thanendrarajan, S Schinke, C Zangari, M van Rhee, F Barlogie, B Mughal, T I Davies, F E Morgan, G J Walker, B A Blood Cancer J Original Article The purpose of this study is to identify prognostic markers and treatment targets using a clinically certified sequencing panel in multiple myeloma. We performed targeted sequencing of 578 individuals with plasma cell neoplasms using the FoundationOne Heme panel and identified clinically relevant abnormalities and novel prognostic markers. Mutational burden was associated with maf and proliferation gene expression groups, and a high-mutational burden was associated with a poor prognosis. We identified homozygous deletions that were present in multiple myeloma within key genes, including CDKN2C, RB1, TRAF3, BIRC3 and TP53, and that bi-allelic inactivation was significantly enriched at relapse. Alterations in CDKN2C, TP53, RB1 and the t(4;14) were associated with poor prognosis. Alterations in RB1 were predominantly homozygous deletions and were associated with relapse and a poor prognosis which was independent of other genetic markers, including t(4;14), after multivariate analysis. Bi-allelic inactivation of key tumor suppressor genes in myeloma was enriched at relapse, especially in RB1, CDKN2C and TP53 where they have prognostic significance. Nature Publishing Group 2017-02 2017-02-24 /pmc/articles/PMC5386330/ /pubmed/28234347 http://dx.doi.org/10.1038/bcj.2017.12 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Original Article Chavan, S S He, J Tytarenko, R Deshpande, S Patel, P Bailey, M Stein, C K Stephens, O Weinhold, N Petty, N Steward, D Rasche, L Bauer, M Ashby, C Peterson, E Ali, S Ross, J Miller, V A Stephens, P Thanendrarajan, S Schinke, C Zangari, M van Rhee, F Barlogie, B Mughal, T I Davies, F E Morgan, G J Walker, B A Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker |
title | Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker |
title_full | Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker |
title_fullStr | Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker |
title_full_unstemmed | Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker |
title_short | Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker |
title_sort | bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying rb1 as an independent prognostic marker |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386330/ https://www.ncbi.nlm.nih.gov/pubmed/28234347 http://dx.doi.org/10.1038/bcj.2017.12 |
work_keys_str_mv | AT chavanss biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT hej biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT tytarenkor biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT deshpandes biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT patelp biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT baileym biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT steinck biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT stephenso biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT weinholdn biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT pettyn biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT stewardd biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT raschel biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT bauerm biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT ashbyc biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT petersone biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT alis biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT rossj biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT millerva biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT stephensp biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT thanendrarajans biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT schinkec biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT zangarim biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT vanrheef biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT barlogieb biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT mughalti biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT daviesfe biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT morgangj biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker AT walkerba biallelicinactivationismoreprevalentatrelapseinmultiplemyelomaidentifyingrb1asanindependentprognosticmarker |